Amneal Pharmaceuticals (AMRX) Scheduled to Post Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. The business had revenue of $616.98 million for the quarter, compared to analysts’ expectations of $630.67 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Trading Up 1.2 %

Shares of Amneal Pharmaceuticals stock opened at $6.12 on Thursday. Amneal Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $6.46. The stock’s 50-day simple moving average is $5.73 and its 200 day simple moving average is $5.24. The stock has a market capitalization of $1.88 billion, a P/E ratio of -19.74 and a beta of 1.33. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of research reports. Barclays boosted their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, January 29th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Piper Sandler upped their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Finally, The Goldman Sachs Group increased their price target on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $7.31.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.